Patient portrayals for indolent systemic mastocytosis (ISM)

The following patient portrayals are fictional examples of adult patients living with ISM and being treated with AYVAKIT that were developed from a review of the published literature. This information does not represent medical advice and individual results may vary. Healthcare providers should make all treatment decisions based on diagnostic criteria, clinical practice guidelines, prescribing information, individual patient circumstances, and their independent clinical judgment.

Review of this material does not substitute for a review of the Prescribing Information for AYVAKIT.

Jeff, a male indolent systemic mastocytosis patient portrayal profileJeff
Sondra, a female indolent systemic mastocytosis patient portrayal profileSondra

Meet Jeff, a working father frustrated by a multiyear journey to ISM diagnosis, and Sondra, a mother of 3 living with ISM who is embarrassed by her ongoing symptoms.1-5

Hypothetical patients. Individual results may vary.

*Quotes have been fictionalized to align with hypothetical patient profiles.

Jeff

Sondra

Jeff, a 45-year-old male indolent systemic mastocytosis patient portrayal profile woodworking

Patient portrayal

Meet Jeff

CalendarAge: 456
CoupleMarried father of 2
Family statusForeman and softball coach
StethoscopeStruggle with ISM symptom burden leads to work and personal impacts2,3,5
Hypothetical patient profile of Jeff's experience prior to ISM diagnosis
Hypothetical patient profile of Jeff's experience prior to ISM diagnosis
Hypothetical patient profile of Jeff after confirmation of ISM diagnosis
Hypothetical patient profile of Jeff after confirmation of ISM diagnosis
Time for a different approach to ISM for hypothetical patient Jeff
Sondra, a female indolent systemic mastocytosis patient portrayal profile with her dog

Patient portrayal

Meet Sondra

CalendarAge: 476
CoupleMarried mother of 3
Family statusStay-at-home mom
StethoscopeStruggling to manage disease and symptoms3,4
Hypothetical patient profile of Sondra's experience prior to ISM diagnosis
Hypothetical patient profile of Sondra's experience prior to ISM diagnosis
Hypothetical patient profile of Sondra after confirmation of ISM diagnosis
Hypothetical patient profile of Sondra after confirmation of ISM diagnosis
Time for a different approach to ISM for hypothetical patient Sondra
Time for a different approach to ISM for hypothetical patient Sondra
Hypothetical patient results for Sondra

*Quotes have been fictionalized to align with hypothetical patient profiles.
FDA=Food and Drug Administration; KIT=KIT proto-oncogene, receptor tyrosine kinase; NSAID=non-steroidal anti-inflammatory drug; WHO=World Health Organization.

Access resources for you and your patients taking AYVAKIT

ACCESS AND SUPPORT

Patient portrayal

ISM patient and caregiver

References: 1. Ungerstedt J et al. Cancers. 2022;14(16):3942. 2. Pardanani A. Am J Hematol. 2023;98(7):1097-1116. 3. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2023. 4. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172. 5. van Anrooij B et al. Allergy. 2016;71(11):1585-1593. 6. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024. 7. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited April 24, 2024]. (WHO Classification of Tumours Series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who.int/chapters/63 8. Dranitsaris G et al. J Oncol Pharm Pract. Published online December 27, 2023. doi:10.1177/10781552231221149 9. Siebenhaar F et al. Immunol Allergy Clin North Am. 2014;34(2):433-447. 10. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525. 11. Kristensen T et al. Am J Hematol. 2014;89(5):493-498. 12. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372.